Navigation Links
Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting

1 EOquin Instillation Immediately Following Transurethral Resection is Well Tolerated in Phase 2b Bladder Cancer Study

IRVINE, Calif., April 19, 2007 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc., today announced results of a Phase 2b study of EOquin, in non-invasive bladder cancer and the presentation of preclinical data of SPI (IRL)-1620 and satraplatin at the annual meeting of the American Association of Cancer Research, held at the Los Angeles Convention Center in Los Angeles, California April 14-18, 2007.

Abstract #LB-359 -- Effect on Wound Healing and Pharmacokinetics of Single Intravesical Administration of Apaziquone (EOquin(R)) Immediately Following Transurethral Resection of Superficial Bladder Cancer -- Initial Results of a Phase 2b Study

The Phase 2b study was a multicenter, single-arm, open-label safety study with the objective of assessing the effect on surgical wound healing and systemic absorption of EOquin when given intravesically as a single dose immediately after transurethral resection of bladder tumor (TUR-BT). EOquin in 40mL of instillate was instilled into the bladder within 6 hours of TUR-BT. After an hour, the bladder was drained and patients were assessed for adverse events during the one-hour retention. Wound healing was assessed by cystoscopy performed at postoperative day 85.

Results

A total of 23 patients were enrolled and 20 patients received EOquin immediately following TUR-BT. EOquin instillation and retention were well tolerated by all patients, and no deaths or dropouts were reported. Four Serious Adverse Events were reported in three patients: two hematuria, one bacterial cystitis, and one urinary retention. Ten patients were examined by cystoscopy at day 85 and all showed complete reepithelialization without evidence of impaired wound healing. Neither the parent drug (EO9) nor its metabolite (EO54a) was detected in plasma samples utili
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
2. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:8/29/2014)... N.C. , Aug. 29, 2014 The ... of regulatory and marketplace changes. CI leaders who adjust ... In a new Best Practices, LLC study ... of actionable insights, including: - Use secondary ... than primary research - Internal staff who ...
(Date:8/29/2014)... Aug. 29, 2014  A Boston Scientific Corporation ... on stent removability and preliminary long term stricture ... in the August issue of the peer-reviewed journal, ... is being conducted in 11 countries and ... self-expanding metal stents (FCSEMS) after extended indwell (i.e., ...
(Date:8/29/2014)... Aug. 29, 2014 Thoratec Corporation (NASDAQ: ... circulatory support therapies to save, support and restore failing ... 2014 Morgan Stanley Global Healthcare Conference on Wednesday, September ... and Chief Executive Officer, will provide an update on ... (9:55 a.m., Pacific Daylight Time).   A ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4
... May 20 The owner and operator of a Houston-area ... program, announced the Departments of Justice and Health and Human Services (HHS). ... William M. ... fraud before U.S. District Judge David Hittner in U.S. District ...
... May 20 Inverness Medical Innovations, Inc. (NYSE: ... charge of their health at home through the merger of rapid ... Citi Global Health Care Conference being held May 26 through ... New York City .  Jon Russell, Vice President, Finance, will attend. ...
Cached Medicine Technology:Houston-Area Durable Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutrition Supplies 2Houston-Area Durable Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutrition Supplies 3
(Date:9/1/2014)... HealthDay Reporter SATURDAY, Aug. 30, ... experimental drug was more effective than standard treatment at ... According to the study authors, the trial was stopped ... drug, dubbed LCZ696. In the trial, 26.5 ... either died or were hospitalized due to heart failure, ...
(Date:9/1/2014)... MONDAY, Sept. 1, 2014 (HealthDay News) -- Watching action shows ... study contends. People eat much more snack food while ... to the Cornell University researchers. "We find that if ... see more action too," study author Aner Tal, of the ... release. "In other words, the more distracting the program is, ...
(Date:9/1/2014)... London, UK (PRWEB) September 01, 2014 ... in developing more effective treatments for Alzheimer's disease ... disease. Uncertainties also exist regarding the diagnosis of ... hence, the lack of appropriate diagnostic tests. ... range of the greatest breakthroughs in the medicine ...
(Date:9/1/2014)... More than 200 Lipitor lawsuit ( ... litigation that continues to progress in the U.S. District ... , A federal Case List published on August ... cholesterol medication by plaintiffs who developed Type 2 diabetes ... Inc. failed to adequately warn patients and their doctors ...
(Date:9/1/2014)... The B-cell non-Hodgkin’s Lymphoma (NHL) treatment ... markets (the US, France, Italy, Germany, Spain and the ... by 2018. , The competitive landscape in the B-cell ... and the UK is poised to undergo a dramatic ... four largest B-cell NHL indications, which includes Diffuse Large ...
Breaking Medicine News(10 mins):Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4
... Nov. 29 Boston Scientific,Corporation (NYSE: BSX ... Food,and Drug Administration (FDA) advisory panel to approve ... stent system. The,PROMUS and XIENCE V stent systems ... Abbott in international markets. Both stent,systems would be ...
... 29 "CT scans are helping to,save countless ... disorders. Indeed, the New England Journal of Medicine ... one of the top 11,innovations of the past ... that detect and treat life threatening diseases CT,scans ...
... International Website goes beyond, Typical ,Best, and ... Affecting ... Determining health risks and the,quality of medical care ... published MEDEX 360m International Healthcare Rating,System, high standards of ...
... November 29 Bavarian Nordic,reports the successful completion ... healthy subjects who received either one or two ... of this,study are seen as the pivotal step ... registration trials in order to achieve a BLA ...
... genetics appear to be key factors, researchers say , , ... -- over and above socio-economic factors -- appear to ... breast cancer, U.S. researchers are reporting. , One new ... cancer patients and their white counterparts, indicating that cancer ...
... by a University of Pennsylvania biologist in the tick-infested woods ... that mice are the main animal reservoir for Lyme disease ... Proceedings of the Royal Society B, demonstrates that chipmunks and ... that account for major outbreaks. , According to the study, white-footed ...
Cached Medicine News:Health News:Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System 2Health News:Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System 3Health News:Statement by MITA Vice President Andrew Whitman on the Benefits of CT Scans Relative to Radiation Dose Risks 2Health News:MEDEX 360m Rates the State of Global Medical Care for Travelers 2Health News:Bavarian Nordic Reports Positive Data from First EUA Enabling Study with IMVAMUNE(R) Smallpox Vaccine Candidate 2Health News:Studies Reveal Why Breast Cancer Hits Black Women Harder 2Health News:Studies Reveal Why Breast Cancer Hits Black Women Harder 3Health News:University of Pennsylvania study reveals inconspicuous hosts in the Lyme disease epidemic 2
Toxoplasma IgG II ELISA...
ELISA kit for CMV CAP M....
Blunt tipped forceps with tungsten carbide treated jaws for enhanced gripping and removal of small sized foreign bodies....
Blunt tipped forceps with a thin tip angled at approximately 135 and hollowed out "notch" on the interior of the distal end. Tip is shaped like a pic when in the closed position. For membrane peeling...
Medicine Products: